Bruno Gagnon
Corporate Officer/Principal presso OPTHEA LIMITED
Posizioni attive di Bruno Gagnon
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| OPTHEA LIMITED | Corporate Officer/Principal | 01/07/2022 | - |
Storia della carriera di Bruno Gagnon
Precedenti posizioni note di Bruno Gagnon
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| BIOMARIN PHARMACEUTICAL INC. | Direttore operativo | - | - |
| EIDOS THERAPEUTICS, INC. | Direttore operativo | - | - |
Formazione di Bruno Gagnon
| University of Montréal | Graduate Degree |
| Université Laval | Undergraduate Degree |
Statistiche
Distribuzione geografica
| Stati Uniti | 3 |
| Canada | 3 |
| Australia | 2 |
Posizioni
| Chief Operating Officer | 2 |
| Corporate Officer/Principal | 1 |
| Graduate Degree | 1 |
Settori
| Health Technology | 4 |
| Consumer Services | 3 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| OPTHEA LIMITED | Health Technology |
| BIOMARIN PHARMACEUTICAL INC. | Health Technology |
| Aziende private | 1 |
|---|---|
Eidos Therapeutics, Inc.
 Eidos Therapeutics, Inc. BiotechnologyHealth Technology Eidos Therapeutics, Inc. focuses on addressing the large and growing unmet need in diseases caused by transthyretin (TTR) amyloidosis (ATTR). Its product include the AG10, an orally-administered small molecule designed to potently stabilize TTR, suggesting a treatment with the potential to halt the progression of ATTR. The company was founded by Graef Isabella and Alhamadsheh Mamoun on August 6, 2013 and is headquartered in San Francisco, CA. | Health Technology |
- Borsa valori
- Insiders
- Bruno Gagnon
- Esperienza
